Intellia Therapeutics gets FDA lift of clinical hold on Phase 3

 

Intellia Therapeutics gets FDA lift of clinical hold on Phase 3 MAGNITUDE ATTR-CM trial, upsizes ATM equity program to $1.04 billion

• FDA lift of the MAGNITUDE clinical hold allows enrollment in the Phase 3 ATTR-CM trial to resume.
• Upsized at-the-market equity offering program to $1.04 billion was disclosed in an SEC filing today following the FDA decision.
• MAGNITUDE is a Phase 3 ATTR-CM trial evaluating nexiguran ziclumeran (NTLA-2001).

https://finviz.com/quote.ashx?t=NTLA&p=d